A Single Dose, Three-Arm, Placebo-Controlled, Phase I Study of the Bradykinin B2 Receptor Antagonist Anatibant (LF16-0687Ms) in Patients with Severe Traumatic Brain Injury-Reference-Cited by-同舟云学术

A Single Dose, Three-Arm, Placebo-Controlled, Phase I Study of the Bradykinin B2 Receptor Antagonist Anatibant (LF16-0687Ms) in Patients with Severe Traumatic Brain Injury

Published:2005-12 Issue:12 Volume:22 Page:1444-1455
ISSN:0897-7151
Container-title:Journal of Neurotrauma
language:en
Short-container-title:Journal of Neurotrauma

Author:

Marmarou Anthony¹,Guy Martine²,Murphey Laine³,Roy Francis²,Layani Laure²,Combal Jean-Philippe²,Marquer Claude²,

Affiliation:

1. ABIC Technical Center, Richmond, Virginia.

2. Laboratoires Fournier S.A., Daix, France.

3. Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Publisher

Mary Ann Liebert Inc

Subject

Clinical Neurology

Link

http://www.liebertpub.com/doi/pdf/10.1089/neu.2005.22.1444

Reference43 articles.

1. Inhibition of bradykinin- and kallikrein-induced cerebral arteriolar dilation by a specific bradykinin antagonist.

2. Brain kininogen following experimental brain injury: evidence for a secondary event

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proline Analogues;Chemical Reviews;2024-06-28

2. Effectiveness of road safety interventions: An evidence and gap map;Campbell Systematic Reviews;2024-01-03

3. Function and structure of bradykinin receptor 2 for drug discovery;Acta Pharmacologica Sinica;2022-09-08

4. Microenvironmental Variations After Blood-Brain Barrier Breakdown in Traumatic Brain Injury;Frontiers in Molecular Neuroscience;2021-11-26

5. Incidence and impact of withdrawal of life-sustaining therapies in clinical trials of severe traumatic brain injury: A systematic review;Clinical Trials;2018-06-04